Tuesday, September 22, 2026
The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Haris Zahoor, MD
an assistant professor of medicine
Baylor College of Medicine in the Dan L Duncan Comprehensive Cancer Center
Published Articles (1)
HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting
September 3, 2026
HIF-2 alpha inhibition, first validated in metastatic clear cell renal cell carcinoma (RCC) with belzutifan, is now extending into new treatment settings.